U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940 [_] Check box if no longer subject of Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). ________________________________________________________________________________ 1. Name and Address of Reporting Person* Ingersoll William Brett -------------------------------------------------------------------------------- (Last) (First) (Middle) c/o Chase Capital Partners 1221 Avenue of the Americas-40th Floor -------------------------------------------------------------------------------- (Street) New York New York 10020 -------------------------------------------------------------------------------- (City) (State) (Zip) ________________________________________________________________________________ 2. Issuer Name and Ticker or Trading Symbol MediChem Life Sciences, Inc. ("MCLS") ________________________________________________________________________________ 3. IRS Identification Number of Reporting Person, if an Entity (Voluntary) ________________________________________________________________________________ 4. Statement for Month/Year October 2000 ________________________________________________________________________________ 5. If Amendment, Date of Original (Month/Year) ================================================================================ 6. Relationship of Reporting Person to Issuer (Check all applicable) [X] Director [_] 10% Owner [_] Officer (give title below) [_] Other (specify below) ________________________________________________________________________________ 7. Individual or Joint/Group Filing (Check applicable line) [X] Form filed by one Reporting Person [_] Form filed by more than one Reporting Person ________________________________________________________________________________ ================================================================================ Table I -- Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned ================================================================================

* If the Form is filed by more than one Reporting Person, see Instruction 4(b)(v). Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. (Print or Type Responses) (Over) (Form 4-07/99) FORM 4 (continued) Table II -- Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) ================================================================================

Explanation of Responses: 1) Pursuant to the Articles of Incorporation of MCR Holdings, Inc. ("MCR"), the parent of MediChem Life Sciences, Inc. (the "Issuer") prior to the merger of the Issuer and MCR, the Class A Convertible Preferred Stock of MCR converted into shares of Class B Redeemable Stock of MCR, which were redeemed for cash, and on a 1-for-1 basis into shares of the Class A Common Stock of MCR. Immediately prior to the close of the Issuer's public offering, MCR was merged into the Issuer and all outstanding shares of the Class A Common Stock of MCR were converted into Common Stock of the Issuer. 2) The amounts shown represent the beneficial ownership of equity securities of the Issuer by Chase MediChem Partners, LLC ("MediChem") after the conversion and merger. A portion of the securities owned by MediChem may be deemed attributable to the reporting person because he is a general partner of Chase Capital Partners ("CCP"), the managing member of Chase Equity Associates, LP ("CEA"). CEA is the non-managing member of MediChem. The actual pro rata portion of the reporting person's beneficial ownership is not readily determinable because it is subject to several variables including CEA's and CCP's internal rate of return and vesting. Mr. Ingersoll disclaims ownership of the securities shown in the table to the extent it exceeds his indirect pecuniary interest in the Issuer. /s/ W. Brett Ingersoll 11/9/00 --------------------------------------------- ---------------------- W. Brett Ingersoll Date ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space provided is insufficient, see Instruction 6 for procedure.

MEDICHEM LIFE SCIENCES INC 4